SHENZHEN, China, July 17, 2015 /PRNewswire/ -- Mindray
Medical International Limited ("Mindray" or the "Company", NYSE:
MR), a leading developer, manufacturer and marketer of medical
devices worldwide, announced today that it completed the
acquisition of the remaining stake in Wuhan Dragonbio Surgical
Implant Co., Ltd. (the "Dragonbio") for a total cash consideration
of RMB 435 million (approximately
US$ 70.2 million) pursuant to the terms of the
definitive agreement entered into on July 7,
2015. The Company now holds 100% of Dragonbio. Dragonbio is
a domestic medical orthopedic products provider that specializes in
trauma, spine, joint and other surgical products.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the safe harbor provisions of the Private securities
Litigation Reform Act of 1995. Statements that are not historical
facts are "forward-looking" statements. These forward-looking
statements can be identified by terminology such as "will,"
"expects," "anticipates," "future," "intends," "plans," "believes,"
"estimates" and similar statements. Mindray may also make written
or oral forward-looking statements in its periodic reports to
the U.S. Securities and Exchange Commission on forms 20-F and
6-K, in its annual report to shareholders, in press releases and
other written materials and in oral statements made by its
officers, directors or employees to third parties. Readers are
cautioned that these forward-looking statements are only
predictions. Forward-looking statements involve inherent risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. A number of important factors
including without limitation, competitive, pricing and other
conditions in China and our
international markets and our ability to effectively address or
respond those conditions; our ability effectively attract and
retain our key employees; the growth and expected growth of the
medical device market in China and
internationally; applicable government policies and regulations;
our ability to satisfy the requirements imposed by relevant
regulatory bodies; market acceptance of our products; our
expectations regarding demand for our products; our ability to
expand our production, our sales and distribution network and other
aspects of our operations; our ability to stay abreast of market
trends and technological advances; our ability to effectively
protect our intellectual property rights and not infringe on the
intellectual property rights of others; our ability to settle
disputes with our customers and suppliers; and general economic and
business conditions in the countries in which we operate, could
cause actual results to differ materially from those contained in
any forward-looking statement. For a discussion of other important
factors that could adversely affect our business, financial
condition, results of operations and prospects, see "Risk Factors"
beginning on page 6 of our annual report on Form 20-F which was
filed on April 16, 2015. Potential
risks and uncertainties include, but are not limited to, risks
outlined in Mindray's filings with the U.S. Securities and
Exchange Commission, including its registration statements on Form
F-1, F-3 and 20-F, in each case as amended. Any projections in this
release are based on limited information currently available to us,
which is subject to change. Although such projections and the
factors influencing them will likely change, Mindray does not
necessarily undertake any obligation to update any forward-looking
statements, except as required under applicable law. Such
forward-looking statements speak only as of the date of this
release.
About Mindray
We are a leading developer, manufacturer and marketer of medical
devices worldwide. We maintain our global headquarters
in Shenzhen, China, U.S.
headquarters in Mahwah, New Jersey and multiple sales
offices in major international markets. From our main manufacturing
and engineering base in China, we supply through our worldwide
distribution network a broad range of products across three primary
business segments, namely patient monitoring and life support,
in-vitro diagnostics, and medical imaging systems. For more
information, please visit http://ir.mindray.com.
For investor and media inquiries, please contact:
In China:
Cathy Gao
Mindray Medical International Limited
Tel: +86-755-8188-8023
Email: cathy.gao@mindray.com
In the U.S:
Hoki Luk
Western Bridge, LLC
Tel: +1-646-808-9150
Email: hoki.luk@westernbridgegroup.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mindray-medical-completes-acquisition-of-wuhan-dragonbio-300114830.html
SOURCE Mindray Medical International Limited